about
High concentration of raltegravir in semen of HIV-infected men: results from a substudy of the EASIER-ANRS 138 trial.The French national prospective cohort of patients co-infected with HIV and HCV (ANRS CO13 HEPAVIH): early findings, 2006-2010.Liver fibrosis regression and progression during controlled hepatitis B virus infection among HIV-HBV patients treated with tenofovir disoproxil fumarate in France: a prospective cohort study.A single HIV-1 cluster and a skewed immune homeostasis drive the early spread of HIV among resting CD4+ cell subsets within one month post-infectionIs clinical practice concordant with the changes in guidelines for antiretroviral therapy initiation during primary and chronic HIV-1 infection? The ANRS PRIMO and COPANA cohorts.Switch from enfuvirtide to raltegravir lowers plasma concentrations of darunavir and tipranavir: a pharmacokinetic substudy of the EASIER-ANRS 138 trial.Plasma cholesterol efflux capacity from human THP-1 macrophages is reduced in HIV-infected patients: impact of HAARTDendritic Cells from HIV Controllers Have Low Susceptibility to HIV-1 Infection In Vitro but High Capacity to Capture HIV-1 Particles.Burden of HIV disease and comorbidities on the chances of maintaining employment in the era of sustained combined antiretoviral therapies useComparison of the antiviral activity of adefovir and tenofovir on hepatitis B virus in HIV-HBV-coinfected patients.Infectious Zika virus in vaginal secretions from an HIV-infected woman, France, August 2016.Drug resistance and tropism as markers of the dynamics of HIV-1 DNA quasispecies in blood cells of heavily pretreated patients who achieved sustained virological suppression.Rates and determinants of hepatitis B 'e' antigen and hepatitis B surface antigen seroclearance during long-term follow-up of patients coinfected with HIV and hepatitis B virus.Efficacy and safety of direct-acting antiviral regimens in HIV/HCV-co-infected patients - French ANRS CO13 HEPAVIH cohort.All-oral Direct-acting Antiviral Regimens in HIV/Hepatitis C Virus-coinfected Patients With Cirrhosis Are Efficient and Safe: Real-life Results From the Prospective ANRS CO13-HEPAVIH Cohort.Development of anti-hepatitis B surface (HBs) antibodies after HBs antigen loss in HIV-hepatitis B virus co-infected patients.Nonorgan-specific autoantibodies in HIV-infected patients in the HAART era.Renal outcomes after up to 8 years of tenofovir exposure in HIV-HBV-coinfected patients.Decay of ccc-DNA marks persistence of intrahepatic viral DNA synthesis under tenofovir in HIV-HBV co-infected patients.Cannabis Use and Reduced Risk of Insulin Resistance in HIV-HCV Infected Patients: A Longitudinal Analysis (ANRS CO13 HEPAVIH).Combined ART started during acute HIV infection protects central memory CD4+ T cells and can induce remission.Telaprevir for HIV/hepatitis C virus-coinfected patients failing treatment with pegylated interferon/ribavirin (ANRS HC26 TelapreVIH): an open-label, single-arm, phase 2 trial.Role of a 48-week pegylated interferon therapy in hepatitis B e antigen positive HIV-co-infected patients on cART including tenofovir: EMVIPEG study.Liver fibrosis changes in HIV-HBV-coinfected patients: clinical, biochemical and histological effect of long-term tenofovir disoproxil fumarate use.Does early antiretroviral treatment prevent liver fibrosis in HIV/HCV-coinfected patients?Antiretroviral therapy and sustained virological response to HCV therapy are associated with slower liver fibrosis progression in HIV-HCV-coinfected patients: study from the ANRS CO 13 HEPAVIH cohort.High incidence of treatment-induced and vaccine-escape hepatitis B virus mutants among human immunodeficiency virus/hepatitis B-infected patients.Current management and recommendations on hepatitis B therapy in HIV-coinfected patients.Low incidence of precore W28* mutant variants in treated hepatitis B virus and human immunodeficiency virus co-infected patients.Kinetics of hepatitis B surface and envelope antigen and prediction of treatment response to tenofovir in antiretroviral-experienced HIV-hepatitis B virus-infected patients.Impact of chronic hepatitis C and/or D on liver fibrosis severity in patients co-infected with HIV and hepatitis B virus.Maraviroc-induced decrease in circulating bacterial products is not linked to an increase in immune activation in HIV-infected individuals.Correction: Is Clinical Practice Concordant with the Changes in Guidelines for Antiretroviral Therapy Initiation during Primary and Chronic HIV-1 Infection? The ANRS PRIMO and COPANA Cohorts.Major role of hepatitis B genotypes in liver fibrosis during coinfection with HIV.Performance of 11 biomarkers for liver fibrosis assessment in HIV/HBV co-infected patients.Prevalence of HIV-related pulmonary arterial hypertension in the current antiretroviral therapy era.Comparative RNA quantification of HIV-1 group M and non-M with the Roche Cobas AmpliPrep/Cobas TaqMan HIV-1 v2.0 and Abbott Real-Time HIV-1 PCR assays.Epidemiology, diagnosis and treatment of chronic hepatitis B in HIV-infected patients (EPIB 2005 STUDY)Correlates of poor perceived health among individuals living with HIV and HBV chronic infections: a longitudinal assessment
P50
Q33613775-E5B8E780-CAF0-4CA1-BA0B-7DAD75C07952Q33726091-B0E7D795-E7F7-47CF-8767-CAC086DE1A32Q33787655-BF4EDF7F-FBFB-471F-80F2-E457D1D92E83Q34731350-15CDA4CB-C65F-4452-9C50-D9F707CC8DBBQ34926786-385D5454-F353-42D5-B6D2-66841820BEB3Q35065925-1B8A7C83-F753-45F1-A24C-D43365EAAD15Q35120957-A1B8ABA7-00BE-4FE4-9C0C-F6764A66D748Q36098858-200C3845-278C-46D0-A691-192D4119BB63Q36924509-9AE2B75D-F509-4295-9DFC-FCDFB04D952EQ37149701-B3EC7159-B4C0-441A-B368-3AB0924C0BA1Q37660934-E4D41447-F2E8-4B0C-BA5D-3AE4A3E41279Q38383070-AB85BB86-DDDB-4066-BE52-54EECA68BADBQ38918604-DB2DAF5E-5088-4DDC-9888-DE8BE5BED703Q38943318-B535A0CB-ADE1-454B-8E78-22E8122698D6Q39673593-027E2233-7485-4A8D-B204-C7ABEC27C12EQ40058939-1FC32B6B-AA07-4062-9760-A9D2A785D448Q40303001-9D6A6A78-20B4-4EC0-BE09-86310D1FA604Q40565568-0B0A205F-5656-4A2C-8974-FC363686EE7EQ40664631-2DE6AA5C-6AB5-4E2E-A004-2850F9EEA296Q41207222-50021F2B-A8A2-4963-BDEF-90064E4093B0Q41299483-2E6B72FD-104C-4279-8E16-5048B159A752Q42199004-3EC729E2-92E6-4296-B79B-72DC721F9C63Q42215537-DBAADE2F-4CF3-4BE5-B22D-AA913B903BAFQ42839652-AD353419-29EA-4CDC-A6A0-A9A0D8DEE689Q42984589-AEA238DB-BE06-4CA7-AA50-B6656749E142Q42984981-81947247-65DE-4790-A792-311E9B7FE73FQ43586321-F9D6B5E2-AF02-4AB5-8633-2BFE3D8E19EEQ44257466-0A2297E2-0D7E-44D9-80F1-FF7AAC86959EQ45324339-3C57369E-DA34-455C-907F-256FCDF81910Q45359671-92D3E54E-2335-4E1C-9C67-1DA3ECD47DF8Q45399150-06A5EAF6-F506-4458-9E2E-5A8C7ED9CE06Q46581707-82EFAC7C-C7E3-445C-A51E-34A64D9DC465Q46848967-98C142E5-63DB-43EB-ADD6-27C3E1B0B6ECQ46913882-B4A761C0-872A-44F9-8BA3-6FDD3F21BD4DQ51836061-8DC5B723-CFED-45BC-90BC-779DE88F9F7CQ51903874-E423DC1B-22EB-44EC-88DF-0ED385517376Q54396877-A132E22E-2693-4315-BDDC-8D8E02591ECBQ56833902-59346405-E297-4E8D-90AB-C526885D0658Q58106560-DE52039C-00A8-4BEA-8642-E90E21DAFB58
P50
description
researcher ORCID ID = 0000-0003-2049-8048
@en
wetenschapper
@nl
name
Caroline Lascoux-Combe
@ast
Caroline Lascoux-Combe
@en
Caroline Lascoux-Combe
@es
Caroline Lascoux-Combe
@nl
type
label
Caroline Lascoux-Combe
@ast
Caroline Lascoux-Combe
@en
Caroline Lascoux-Combe
@es
Caroline Lascoux-Combe
@nl
prefLabel
Caroline Lascoux-Combe
@ast
Caroline Lascoux-Combe
@en
Caroline Lascoux-Combe
@es
Caroline Lascoux-Combe
@nl
P106
P21
P31
P496
0000-0003-2049-8048